AAPL339.75+0.77 (+0.23%) ▲|ABBV265.21+0.73 (+0.28%) ▲|ABT103.69+0.71 (+0.69%) ▲|ACN183.72-2.39 (-1.28%) ▼|ADBE238.25-11.27 (-4.52%) ▼|AMAT472.46+8.22 (+1.77%) ▲|AMD623.77+8.25 (+1.34%) ▲|AMGN410.24+17.08 (+4.34%) ▲|AMT175.25+0.65 (+0.37%) ▲|AMZN254.98-3.47 (-1.34%) ▼|AVGO364.54+1.88 (+0.52%) ▲|AXP305.07-8.52 (-2.72%) ▼|BA197.72-3.43 (-1.71%) ▼|BAC56.20-1.76 (-3.04%) ▼|BKNG164.22-4.30 (-2.55%) ▼|BLK1,066.66-23.61 (-2.17%) ▼|BMY62.25-0.37 (-0.59%) ▼|BNY150.17-3.72 (-2.42%) ▼|BRK-B503.49+1.48 (+0.29%) ▲|C132.47-2.58 (-1.91%) ▼|CAT808.01-8.49 (-1.04%) ▼|CL87.05+0.79 (+0.92%) ▲|CMCSA22.42-0.51 (-2.22%) ▼|COF200.55-4.37 (-2.13%) ▼|COP125.27-2.26 (-1.77%) ▼|COST899.41+0.93 (+0.10%) ▲|CRM233.28-3.14 (-1.33%) ▼|CSCO106.44-5.02 (-4.50%) ▼|CVS87.10-0.50 (-0.57%) ▼|CVX202.41-1.26 (-0.62%) ▼|DE703.12+18.39 (+2.69%) ▲|DHR221.09+5.25 (+2.43%) ▲|DIS103.82-0.41 (-0.39%) ▼|DUK116.31-0.43 (-0.37%) ▼|EMR154.19+2.47 (+1.63%) ▲|FDX295.94+0.15 (+0.05%) ▲|GD343.39-10.51 (-2.97%) ▼|GE319.22+0.21 (+0.07%) ▲|GEV950.28+4.06 (+0.43%) ▲|GILD152.67+2.11 (+1.40%) ▲|GM83.45-0.50 (-0.60%) ▼|GOOG347.41-3.46 (-0.99%) ▼|GOOGL351.16-3.81 (-1.07%) ▼|GS949.49-9.90 (-1.03%) ▼|HD305.35+8.15 (+2.74%) ▲|HON211.85+5.37 (+2.60%) ▲|IBM231.38-0.55 (-0.24%) ▼|INTC123.86+2.08 (+1.71%) ▲|INTU292.35-11.77 (-3.87%) ▼|ISRG402.09+0.44 (+0.11%) ▲|JNJ269.19-0.28 (-0.10%) ▼|JPM340.00-12.04 (-3.42%) ▼|KO88.61+1.49 (+1.71%) ▲|LIN464.91+7.41 (+1.62%) ▲|LLY1,170.14+5.25 (+0.45%) ▲|LMT522.34-13.06 (-2.44%) ▼|LOW196.08+5.10 (+2.67%) ▲|LRCX310.96+8.68 (+2.87%) ▲|MA555.89-11.76 (-2.07%) ▼|MCD250.35+2.47 (+1.00%) ▲|MDLZ61.08+0.91 (+1.51%) ▲|MDT90.77-0.98 (-1.07%) ▼|META736.60-4.65 (-0.63%) ▼|MMM169.30+4.33 (+2.62%) ▲|MO68.64+0.11 (+0.16%) ▲|MRK150.91+1.41 (+0.94%) ▲|MS200.18-5.94 (-2.88%) ▼|MSFT498.00-3.61 (-0.72%) ▼|MU1,096.16+52.20 (+5.00%) ▲|NEE79.26-0.37 (-0.46%) ▼|NFLX72.16-1.20 (-1.64%) ▼|NKE36.10+0.00 (+0.00%) ▲|NOW137.00-0.68 (-0.49%) ▼|NVDA228.87+1.49 (+0.66%) ▲|ORCL149.20+0.64 (+0.43%) ▲|PEP131.19+1.60 (+1.23%) ▲|PFE27.93+0.19 (+0.68%) ▲|PG148.22+2.14 (+1.47%) ▲|PLTR184.99+1.92 (+1.05%) ▲|PM190.23+2.75 (+1.47%) ▲|QCOM198.27+4.04 (+2.08%) ▲|RTX190.99-3.35 (-1.72%) ▼|SBUX95.11+0.21 (+0.22%) ▲|SCHW100.35-6.53 (-6.11%) ▼|SO85.15-0.31 (-0.36%) ▼|SPG205.95+0.97 (+0.47%) ▲|T25.10-0.35 (-1.38%) ▼|TMO658.52-0.24 (-0.04%) ▼|TMUS162.41-2.86 (-1.73%) ▼|TSLA378.90+3.69 (+0.98%) ▲|TXN271.41+0.54 (+0.20%) ▲|UBER69.89-0.95 (-1.34%) ▼|UNH372.95-4.61 (-1.22%) ▼|UNP274.41+4.78 (+1.77%) ▲|UPS95.87+1.12 (+1.18%) ▲|USB59.44-1.00 (-1.65%) ▼|V362.04-7.91 (-2.14%) ▼|VZ46.45-1.23 (-2.58%) ▼|WFC83.15-3.39 (-3.92%) ▼|WMT110.12+2.68 (+2.49%) ▲|XOM158.71+0.41 (+0.26%) ▲|AAPL339.75+0.77 (+0.23%) ▲|ABBV265.21+0.73 (+0.28%) ▲|ABT103.69+0.71 (+0.69%) ▲|ACN183.72-2.39 (-1.28%) ▼|ADBE238.25-11.27 (-4.52%) ▼|AMAT472.46+8.22 (+1.77%) ▲|AMD623.77+8.25 (+1.34%) ▲|AMGN410.24+17.08 (+4.34%) ▲|AMT175.25+0.65 (+0.37%) ▲|AMZN254.98-3.47 (-1.34%) ▼|AVGO364.54+1.88 (+0.52%) ▲|AXP305.07-8.52 (-2.72%) ▼|BA197.72-3.43 (-1.71%) ▼|BAC56.20-1.76 (-3.04%) ▼|BKNG164.22-4.30 (-2.55%) ▼|BLK1,066.66-23.61 (-2.17%) ▼|BMY62.25-0.37 (-0.59%) ▼|BNY150.17-3.72 (-2.42%) ▼|BRK-B503.49+1.48 (+0.29%) ▲|C132.47-2.58 (-1.91%) ▼|CAT808.01-8.49 (-1.04%) ▼|CL87.05+0.79 (+0.92%) ▲|CMCSA22.42-0.51 (-2.22%) ▼|COF200.55-4.37 (-2.13%) ▼|COP125.27-2.26 (-1.77%) ▼|COST899.41+0.93 (+0.10%) ▲|CRM233.28-3.14 (-1.33%) ▼|CSCO106.44-5.02 (-4.50%) ▼|CVS87.10-0.50 (-0.57%) ▼|CVX202.41-1.26 (-0.62%) ▼|DE703.12+18.39 (+2.69%) ▲|DHR221.09+5.25 (+2.43%) ▲|DIS103.82-0.41 (-0.39%) ▼|DUK116.31-0.43 (-0.37%) ▼|EMR154.19+2.47 (+1.63%) ▲|FDX295.94+0.15 (+0.05%) ▲|GD343.39-10.51 (-2.97%) ▼|GE319.22+0.21 (+0.07%) ▲|GEV950.28+4.06 (+0.43%) ▲|GILD152.67+2.11 (+1.40%) ▲|GM83.45-0.50 (-0.60%) ▼|GOOG347.41-3.46 (-0.99%) ▼|GOOGL351.16-3.81 (-1.07%) ▼|GS949.49-9.90 (-1.03%) ▼|HD305.35+8.15 (+2.74%) ▲|HON211.85+5.37 (+2.60%) ▲|IBM231.38-0.55 (-0.24%) ▼|INTC123.86+2.08 (+1.71%) ▲|INTU292.35-11.77 (-3.87%) ▼|ISRG402.09+0.44 (+0.11%) ▲|JNJ269.19-0.28 (-0.10%) ▼|JPM340.00-12.04 (-3.42%) ▼|KO88.61+1.49 (+1.71%) ▲|LIN464.91+7.41 (+1.62%) ▲|LLY1,170.14+5.25 (+0.45%) ▲|LMT522.34-13.06 (-2.44%) ▼|LOW196.08+5.10 (+2.67%) ▲|LRCX310.96+8.68 (+2.87%) ▲|MA555.89-11.76 (-2.07%) ▼|MCD250.35+2.47 (+1.00%) ▲|MDLZ61.08+0.91 (+1.51%) ▲|MDT90.77-0.98 (-1.07%) ▼|META736.60-4.65 (-0.63%) ▼|MMM169.30+4.33 (+2.62%) ▲|MO68.64+0.11 (+0.16%) ▲|MRK150.91+1.41 (+0.94%) ▲|MS200.18-5.94 (-2.88%) ▼|MSFT498.00-3.61 (-0.72%) ▼|MU1,096.16+52.20 (+5.00%) ▲|NEE79.26-0.37 (-0.46%) ▼|NFLX72.16-1.20 (-1.64%) ▼|NKE36.10+0.00 (+0.00%) ▲|NOW137.00-0.68 (-0.49%) ▼|NVDA228.87+1.49 (+0.66%) ▲|ORCL149.20+0.64 (+0.43%) ▲|PEP131.19+1.60 (+1.23%) ▲|PFE27.93+0.19 (+0.68%) ▲|PG148.22+2.14 (+1.47%) ▲|PLTR184.99+1.92 (+1.05%) ▲|PM190.23+2.75 (+1.47%) ▲|QCOM198.27+4.04 (+2.08%) ▲|RTX190.99-3.35 (-1.72%) ▼|SBUX95.11+0.21 (+0.22%) ▲|SCHW100.35-6.53 (-6.11%) ▼|SO85.15-0.31 (-0.36%) ▼|SPG205.95+0.97 (+0.47%) ▲|T25.10-0.35 (-1.38%) ▼|TMO658.52-0.24 (-0.04%) ▼|TMUS162.41-2.86 (-1.73%) ▼|TSLA378.90+3.69 (+0.98%) ▲|TXN271.41+0.54 (+0.20%) ▲|UBER69.89-0.95 (-1.34%) ▼|UNH372.95-4.61 (-1.22%) ▼|UNP274.41+4.78 (+1.77%) ▲|UPS95.87+1.12 (+1.18%) ▲|USB59.44-1.00 (-1.65%) ▼|V362.04-7.91 (-2.14%) ▼|VZ46.45-1.23 (-2.58%) ▼|WFC83.15-3.39 (-3.92%) ▼|WMT110.12+2.68 (+2.49%) ▲|XOM158.71+0.41 (+0.26%) ▲|
18.2 C
New York
Wednesday, September 23, 2026

Tag: program

newssourceFORcompanyinformationcontent1releasesmarket

Compagnie de l’Odet : Availability of the description of share buyback program

COMPAGNIE DE L'ODET

European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome...

LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...

ADT partners with All Things Made New to launch safe spaces for youth in Dallas County

BOCA RATON, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT), a provider of smart home and small business security solutions, today announced a $100,000 donation to support All Things Made New, a Dallas-area nonprofit that helps teens and young adults through mentorship, life skills coaching and access to essential resources.

SUBARU RELEASES SEVENTH ANNUAL CORPORATE IMPACT REPORT

Honored for the fifth consecutive year as one of America's most community-minded companies by Points of Light Civic 50Recognized for the second year in...

13 Press Releases You Need to See This Week

Including the launch of two Netflix Houses, TI's $60B semiconductor investment,Americans' favorite road trip snacks and the debut of Trump Mobile.  NEW YORK, June 20,...

Electromechanical Actuators in Aircraft Market worth $804.3 million by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 20, 2025 /PRNewswire/ -- The electromechanical actuators in aircraft market is projected to reach USD 804.3 million by 2030, growing from...

Electromechanical Actuators in Aircraft Market worth $804.3 million by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 20, 2025 /PRNewswire/ -- The electromechanical actuators in aircraft market is projected to reach USD 804.3 million by 2030, growing from...

Industrial Cleaning Solvents Market worth $1.55 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 20, 2025 /PRNewswire/ -- The report "Industrial Cleaning Solvents Market by Application (General & Medical Device Cleaning, Metal Cleaners, Disinfectants), End-use Industry (Manufacturing...

Industrial Cleaning Solvents Market worth $1.55 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 20, 2025 /PRNewswire/ -- The report "Industrial Cleaning Solvents Market by Application (General & Medical Device Cleaning, Metal Cleaners, Disinfectants), End-use Industry (Manufacturing...

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.

The Week in Canadian Press Releases: 10 Stories You Need to See

A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, June 20, 2025 /CNW/ - With thousands of press releases published...

Yum China launches AI assistant for store managers, a groundbreaking advance in its tech-driven growth strategy

"Q-Smart" assistant will provide restaurant managers with broad-based support for day-to-day restaurant operations, allowing them to enhance their focus on delivering excellent customer service SHANGHAI,...

Tencent Cloud Empowers Ryde to Elevate In-App Communication in Southeast Asia

HONG KONG, June 20, 2025 /PRNewswire/ -- Tencent Cloud, the cloud business of global leading technology company Tencent, today announced a strategic partnership with Ryde...

GirlStyle Unveils Inaugural “GirlStyle NextGen Glowing Awards 2025,” Illuminating the Future of Beauty

HONG KONG, June 20, 2025 /PRNewswire/ -- The beauty industry marks a significant milestone! GirlStyle, a leading female lifestyle information platform under PressLogic, proudly...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgram

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers